AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15222594 — intervention group
Group type: COMPARATOR
Intervention: Community-based program (CP1)
Number of subjects: 271
Study 10778374 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor protocol
Number of subjects: 405
Study 10778374 — intervention group
Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 405
Study 10778374 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor protocol (for cesarean sections)
Number of subjects: 405
Study 10778374 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (for cesarean sections)
Number of subjects: 405
Study 10778374 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor protocol (for spontaneous vaginal deliveries)
Number of subjects: 405
Study 10778374 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (for spontaneous vaginal deliveries)
Number of subjects: 405
Study 9324179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac by PCA bolus alone (Ket B)
Number of subjects: 191
Study 9324179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac by bolus plus infusion (Ket I)
Number of subjects: 191
Study 9324179 — intervention group
Group type: COMPARATOR
Intervention: Morphine by PCA bolus (morphine)
Number of subjects: 191
Study 8269450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone cervical gel 0.5 mg administered 12 hours prior to oxytocin induction
Number of subjects: 514
Study 8269450 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed during the same period)
Number of subjects: 514
Study 3517967 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20-30mg intravenously
Number of subjects: 20
Study 3517967 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 20
Study 31300303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 33
Study 31300303 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital hearing aids
Number of subjects: 33
Study 31300303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 and hearing aids
Number of subjects: 33
Study 29813147 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 858
Study 29813147 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 858
Study 29813147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 858
Study 29813147 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg and 240 mg
Number of subjects: 858
Study 29813147 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 858
Study 27160898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 9
Study 27160898 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucagon infusion
Number of subjects: 9
Study 23983090 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS and knee group (n = 73)
Number of subjects: 224
Study 23983090 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS and knee group (n = 74)
Number of subjects: 224
Study 23983090 — intervention group
Group type: COMPARATOR
Intervention: Knee group (n = 77)
Number of subjects: 224
Study 22343180 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring removal at 7 days
Number of subjects: 50
Study 22343180 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring removal at 14 days
Number of subjects: 50
Study 22343180 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring removal at 21 days
Number of subjects: 50
Study 22343180 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring (all groups)
Number of subjects: 50
Study 19727794 — intervention group
Group type: EXPERIMENTAL
Intervention: ICare rebound tonometer (RT)
Number of subjects: 327
Study 19727794 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 327
Study 19727794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tonometers (RT and GAT)
Number of subjects: 327
Study 18729781 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of albendazole over 1 year
Number of subjects: 0
Study 18729781 — intervention group
Group type: COMPARATOR
Intervention: Not treated (Control)
Number of subjects: 0
Study 15948265 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (66 Gy)
Number of subjects: 129
Study 15948265 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (50 Gy)
Number of subjects: 129
Study 12362957 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase cognitive-behavioral treatment (Phase 1: 8 weekly sessions of skills training in affect and interpersonal regulation; Phase 2: 8 sessions of modified prolonged exposure)
Number of subjects: 58
Study 12362957 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase cognitive-behavioral treatment
Number of subjects: 58
Study 12362957 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 therapeutic alliance and negative mood regulation skills
Number of subjects: 58
Study 12362957 — intervention group
Group type: COMPARATOR
Intervention: minimal attention wait list
Number of subjects: 58
Study 11208622 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 2,400 microg
Number of subjects: 26
Study 11208622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9622147 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 2955
Study 9622147 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (dose range 1 to 900 mg)
Number of subjects: 2955
Study 9622147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2955
Study 8203683 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid prepaid plan (HMO)
Number of subjects: 0
Study 8203683 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service Medicaid
Number of subjects: 0
Study 3119024 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic factors (measured through census data)
Number of subjects: 78
Study 3119024 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised mortality ratios
Number of subjects: 78
Study 3119024 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct relation for women without reference to husbands' occupations
Number of subjects: 78
Study 3119024 — intervention group
Group type: EXPERIMENTAL
Intervention: Data analysis
Number of subjects: 78
Study 31165607 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality nursing intervention
Number of subjects: 96
Study 31165607 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 96
Study 28797454 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding intervention via prophylactic gastrostomy tube (PGT)
Number of subjects: 124
Study 28797454 — intervention group
Group type: COMPARATOR
Intervention: Usual care (feeding commenced when clinically indicated)
Number of subjects: 124
Study 25712585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobedding (twins cared for in a single cot)
Number of subjects: 234
Study 25712585 — intervention group
Group type: COMPARATOR
Intervention: Standard care (twins cared for in separate cots)
Number of subjects: 234
Study 24239201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with CYP3A4-metabolized statin
Number of subjects: 6795
Study 24239201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with calcium-channel blockers (CCBs)
Number of subjects: 6795
Study 24239201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with CCB and atorvastatin 80 mg daily
Number of subjects: 6795
Study 24239201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with CCB, statin, and proton pump inhibitor
Number of subjects: 6795
Study 24239201 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel versus clopidogrel
Number of subjects: 6795
Study 21485018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized informed consent and a paper handout detailing the risks/benefits of TKA
Number of subjects: 151
Study 21485018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized informed consent, a paper handout, and a video discussing the risks/benefits of TKA
Number of subjects: 151
Study 21485018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized informed consent, a paper handout, a video discussing the risks/benefits of TKA, plus formal nurse education
Number of subjects: 151
Study 21485018 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 151
Study 19062238 — intervention group
Group type: EXPERIMENTAL
Intervention: Free home-pregnancy test kit
Number of subjects: 198
Study 19062238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home-pregnancy test kit)
Number of subjects: 198
Study 16579708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier (polyglactin 910; T)
Number of subjects: 9
Study 16579708 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barrier (ePTFE; C)
Number of subjects: 9
Study 16579708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C and T)
Number of subjects: 9
Study 12720542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 400 mg/day
Number of subjects: 36
Study 12720542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 800 mg/day
Number of subjects: 36
Study 12720542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10671841 — intervention group
Group type: EXPERIMENTAL
Intervention: Zipprep electrodes
Number of subjects: 0
Study 10671841 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiogram electrodes
Number of subjects: 0
Study 9142771 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-interval dosing of aminoglycosides
Number of subjects: 22
Study 8457446 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (betamethasone-17-valerate)
Number of subjects: 10
Study 8457446 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (indomethacin)
Number of subjects: 10
Study 8457446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine (diphenhydramine)
Number of subjects: 10
Study 8457446 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 10
Study 31719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with the median approach (Group M)
Number of subjects: 200
Study 31719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with the paramedian approach (Group PM)
Number of subjects: 200
Study 31719278 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study 28885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 713
Study 28885881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 26162850 — intervention group
Group type: EXPERIMENTAL
Intervention: GVXN SD133 vaccine (2 μg with or without aluminium adjuvant)
Number of subjects: 40
Study 26162850 — intervention group
Group type: EXPERIMENTAL
Intervention: GVXN SD133 vaccine (10 μg with or without aluminium adjuvant)
Number of subjects: 40
Study 26162850 — intervention group
Group type: COMPARATOR
Intervention: GVXN SD133 vaccine (2 μg or 10 μg)
Number of subjects: 40
Study 23329618 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme to improve falling skills during physical education classes
Number of subjects: 33
Study 23329618 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education curriculum (Control)
Number of subjects: 33
Study 21764693 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care (MAC)
Number of subjects: 30
Study 21764693 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 30
Study 21764693 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 30
Study 18362236 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-array 3-dimensional echocardiography (3DE)
Number of subjects: 29
Study 16939923 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil by TCI at 2 ng/ml and propofol 1mg/kg
Number of subjects: 120
Study 16939923 — intervention group
Group type: COMPARATOR
Intervention: remifentanil by TCI, propofol, and doxapram 0.6 mg/kg
Number of subjects: 120
Study 12871872 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up protocol using recombinant FSH (Puregon)
Number of subjects: 83
Study 12871872 — intervention group
Group type: COMPARATOR
Intervention: Step-down protocol using recombinant FSH (Puregon)
Number of subjects: 83
Study 11078902 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 6
Study 11078902 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive feedback
Number of subjects: 6
Study 9010744 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol, 50 micrograms + medroxyprogesterone 10 mg/day for 12 days
Number of subjects: 42
Study 9010744 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg/day + medroxyprogesterone acetate 10 mg/day for 12 days
Number of subjects: 42
Study 9010744 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study 1389931 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg venlafaxine
Number of subjects: 16
Study 1389931 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg venlafaxine
Number of subjects: 16
Study 1389931 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine
Number of subjects: 16
Study 1389931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1389931 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of venlafaxine
Number of subjects: 16
Study 4065165 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position with head tilted down at 10 degrees for 30 min after LP
Number of subjects: 160
Study 4065165 — intervention group
Group type: COMPARATOR
Intervention: Upright position immediately after LP
Number of subjects: 160
Study 29534487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan-rich diet
Number of subjects: 0
Study 29534487 — intervention group
Group type: COMPARATOR
Intervention: Control diet (isocaloric, similar in total fat and fiber content, absent nuts)
Number of subjects: 0
Study 26828426 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance-training intervention during radiation treatment
Number of subjects: 60
Study 26828426 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance-training intervention after radiation treatment
Number of subjects: 60
Study 26828426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (during and after treatment)
Number of subjects: 60
Study 24104856 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h interactive evidence-based educational programme
Number of subjects: 192
Study 24104856 — intervention group
Group type: COMPARATOR
Intervention: 4-h MS-specific stress management programme
Number of subjects: 192
Study 22743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula ligation
Number of subjects: 18
Study 22743626 — intervention group
Group type: COMPARATOR
Intervention: Patent fistula (control group)
Number of subjects: 18
Study 20487612 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent tuberculosis infection (LTBI) screening and treatment
Number of subjects: 447
Study 20487612 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for TB
Number of subjects: 447
Study 20487612 — intervention group
Group type: EXPERIMENTAL
Intervention: Population risk attributable to race and HIV
Number of subjects: 447
Study 20487612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of TB cases
Number of subjects: 447
Study 16775817 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary padding without a drain
Number of subjects: 100
Study 16775817 — intervention group
Group type: COMPARATOR
Intervention: Axillary suction drain
Number of subjects: 100
Study 14977778 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxic hypercapnia (end tidal PCO(2) increased 15% above baseline)
Number of subjects: 28
Study 14977778 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen breathing)
Number of subjects: 28
Study 11564183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangre de grado balm (1% concentration)
Number of subjects: 0
Study 11564183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangre de grado balm
Number of subjects: 0
Study 11564183 — intervention group
Group type: COMPARATOR
Intervention: Sangre de grado balm (Zangrado)
Number of subjects: 0
Study 11564183 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly diluted sangre de grado (1:10,000)
Number of subjects: 0
Study 9215935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic-educational course
Number of subjects: 24
Study 9215935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no course)
Number of subjects: 24
Study 8095558 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 160
Study 8095558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 160
Study 8095558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 160
Study 8095558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 3322096 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. meptazinol 2 mg/kg
Number of subjects: 80
Study 3322096 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. meptazinol 4 mg/kg
Number of subjects: 80
Study 3322096 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 80
Study 31433669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 1978
Study 31433669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 1978
Study 31433669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg and 200 mg
Number of subjects: 1978
Study 28196208 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 8-Gy radiotherapy dose for 1 or 2 bone metastases
Number of subjects: 298
Study 25659986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (Emend®) plus standard antiemetics
Number of subjects: 96
Study 25659986 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard antiemetics
Number of subjects: 96
Study 24142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 90
Study 24142756 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 90
Study 22642610 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational programme (3 hour session) promoting physical activity and healthy lifestyle, with annual group-based maintenance workshops and telephone contact.
Number of subjects: 10
Study 22642610 — intervention group
Group type: COMPARATOR
Intervention: Advice leaflet (control group).
Number of subjects: 10
Study 19528854 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO, 0.5 g of CHO per 18 capsules, approximately 0.13 g x kg(‐1) of body weight)
Number of subjects: 9
Study 19528854 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion (PLAC, gelatin, 0.5 g per 18 capsules, approximately 0.13 g x kg(‐1) of body weight)
Number of subjects: 9
Study 17391920 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative sensations only (hypoaesthetic)
Number of subjects: 184
Study 17391920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed sensations (negative+active)
Number of subjects: 184
Study 17391920 — intervention group
Group type: COMPARATOR
Intervention: No altered sensation
Number of subjects: 184
Study 16220649 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course on managing patient aggression
Number of subjects: 0
Study 16220649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training course)
Number of subjects: 0
Study 12376849 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.6 mg/kg)
Number of subjects: 60
Study 12376849 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamin (0.3 mg/kg)
Number of subjects: 60
Study 12376849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamin (0.6 mg/kg)
Number of subjects: 60
Study 12376849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 microgram/kg)
Number of subjects: 60
Study 9925042 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive intervention (stage‐matched expert‐system reports plus manuals)
Number of subjects: 4653
Study 9925042 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive intervention (stage‐matched manuals)
Number of subjects: 4653
Study 7488690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus serotoninergic medication
Number of subjects: 60
Study 7488690 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 60
Study 2209079 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea compound
Number of subjects: 10
Study 2209079 — intervention group
Group type: COMPARATOR
Intervention: Emollient cream
Number of subjects: 10
Study 6257799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous iodine (2%) applied to fingers
Number of subjects: 15
Study 6257799 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 15
Study 6257799 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo preparation)
Number of subjects: 15
Study 24970720 — intervention group
Group type: COMPARATOR
Intervention: iCBT self‐help format (iCBT‐S)
Number of subjects: 45
Study 24970720 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT group‐therapy format (iCBT‐G)
Number of subjects: 45
Study 24970720 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 45
Study 25833209 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels (continuous and categorical)
Number of subjects: 2104
Study 23311404 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 66
Study 23311404 — intervention group
Group type: COMPARATOR
Intervention: Oral calcitriol
Number of subjects: 66
Study 20708275 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (measured by Pittsburgh Sleep Quality Index - PSQI)
Number of subjects: 56